151 related articles for article (PubMed ID: 31651725)
1. A Case of Anti-NMDA Receptor Encephalitis During Dinutuximab Therapy for Neuroblastoma.
Lowas SR; Lettieri CK
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e127-e129. PubMed ID: 31651725
[TBL] [Abstract][Full Text] [Related]
2. Implementation of immunotherapy into the treatment of neuroblastoma - single center experience with the administration of dinutuximab and management of its adverse effects.
Achbergerová M; Hederová S; Mikesková M; Husáková K; Hrašková A; Kolenová A
Klin Onkol; 2020; 33(5):372-378. PubMed ID: 33108882
[TBL] [Abstract][Full Text] [Related]
3. Dinutuximab for the treatment of pediatric patients with neuroblastoma.
Greenwood K; Foster JH
Drugs Today (Barc); 2017 Sep; 53(9):469-476. PubMed ID: 29238760
[TBL] [Abstract][Full Text] [Related]
4. The safety of dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
Greenwood KL; Foster JH
Expert Opin Drug Saf; 2018 Dec; 17(12):1257-1262. PubMed ID: 30433831
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R
Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
[TBL] [Abstract][Full Text] [Related]
6. Extensive small bowel pneumatosis and ischemia during dinutuximab therapy for high-risk neuroblastoma.
Spencer K; Romberg E; Pinto N
Pediatr Blood Cancer; 2020 Apr; 67(4):e28147. PubMed ID: 31925911
[No Abstract] [Full Text] [Related]
7. Dinutuximab: An Anti-GD2 Monoclonal Antibody for High-Risk Neuroblastoma.
Ploessl C; Pan A; Maples KT; Lowe DK
Ann Pharmacother; 2016 May; 50(5):416-22. PubMed ID: 26917818
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients.
Mastrangelo S; Rivetti S; Triarico S; Romano A; Attinà G; Maurizi P; Ruggiero A
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884452
[TBL] [Abstract][Full Text] [Related]
9. Rhombencephalitis and longitudinal extensive myelitis associated with dinutuximab use in high-risk neuroblastoma.
Atak F; Aydın GB; Öncel İ; Öz S; Oğuz KK
Turk J Pediatr; 2023; 65(3):523-530. PubMed ID: 37395971
[TBL] [Abstract][Full Text] [Related]
10. Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with high-risk neuroblastoma: A case series.
Ding YY; Panzer J; Maris JM; Castañeda A; Gomez-Chiari M; Mora J
Pediatr Blood Cancer; 2018 Jan; 65(1):. PubMed ID: 28748630
[TBL] [Abstract][Full Text] [Related]
11. In brief: Dinutuximab (Unituxin) for high-risk neuroblastoma.
Med Lett Drugs Ther; 2016 Mar; 58(1491):e48. PubMed ID: 27027692
[No Abstract] [Full Text] [Related]
12. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Yu AL; Gilman AL; Ozkaynak MF; Naranjo A; Diccianni MB; Gan J; Hank JA; Batova A; London WB; Tenney SC; Smith M; Shulkin BL; Parisi M; Matthay KK; Cohn SL; Maris JM; Bagatell R; Park JR; Sondel PM
Clin Cancer Res; 2021 Apr; 27(8):2179-2189. PubMed ID: 33504555
[TBL] [Abstract][Full Text] [Related]
14. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
McGinty L; Kolesar J
Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
[TBL] [Abstract][Full Text] [Related]
15. Atypical presentation of anti-N-methyl-D-aspartate receptor encephalitis: two case reports.
Maggio MC; Mastrangelo G; Skabar A; Ventura A; Carrozzi M; Santangelo G; Vanadia F; Corsello G; Cimaz R
J Med Case Rep; 2017 Aug; 11(1):225. PubMed ID: 28810906
[TBL] [Abstract][Full Text] [Related]
16. Induction Chemotherapy With an Anti-GD2 Monoclonal Antibody (Dinutuximab) and Cytokines in Children With Newly Diagnosed High-risk Neuroblastoma: A Case Series.
Gartrell J; Shulkin BL; Helmig S; Caldwell KJ; Furman W; Federico SM
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e692-e696. PubMed ID: 33181583
[TBL] [Abstract][Full Text] [Related]
17. Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model.
Ornell KJ; Taylor JS; Zeki J; Ikegaki N; Shimada H; Coburn JM; Chiu B
Cancer Med; 2020 Apr; 9(8):2891-2903. PubMed ID: 32096344
[TBL] [Abstract][Full Text] [Related]
18. Tolerance of dinutuximab therapy for treatment of high-risk neuroblastoma in two patients with end-stage renal disease on dialysis.
Emberesh M; Rubinstein JD; Young J; Benoit SW; Dandoy CE; Weiss BD
Pediatr Blood Cancer; 2021 Mar; 68(3):e28852. PubMed ID: 33381917
[TBL] [Abstract][Full Text] [Related]
19. Three phenotypes of anti-N-methyl-D-aspartate receptor antibody encephalitis in children: prevalence of symptoms and prognosis.
DeSena AD; Greenberg BM; Graves D
Pediatr Neurol; 2014 Oct; 51(4):542-9. PubMed ID: 25070939
[TBL] [Abstract][Full Text] [Related]
20. Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava.
Achbergerová M; Hederová S; Hrašková A; Kolenová A
Medicine (Baltimore); 2022 Jan; 101(4):e28716. PubMed ID: 35089239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
